系列18F-FDG PET/CT监测食管癌新辅助放化疗后临床完全缓解患者的局部复发
该多中心回顾性研究纳入41例新辅助放化疗后达临床完全缓解且初始拒绝手术、接受主动监测的食管癌患者,评估系列18F-FDG PET/CT检测局部复发的价值。结果显示,24例患者在中位6.5个月复发,复发者SULmax逐渐升高(中位Δ%SULmax +18%),持续cCR者SULmax下降(中位Δ%SULmax -12%),差异有统计学意义(P<0.001)。持续cCR者SULmax在nCRT后11个月最低,提示放射性食管炎基本消退。
要点
- 系列18F-FDG PET/CT或可用于主动监测中检测食管癌局部复发。
- 复发者SULmax逐渐升高(中位Δ%SULmax +18%),持续cCR者下降(中位Δ%SULmax -12%)。
- 持续cCR者SULmax在nCRT后11个月最低,提示放射性食管炎多已消退。
核心结论
- 系列18F-FDG PET/CT可能是主动监测中检测肿瘤复发的有用工具。
- 持续cCR患者SULmax在nCRT后11个月最低,提示放射性食管炎基本消退。
- 上述发现需在更大队列中进一步验证。
研究设计与样本
- 多中心回顾性研究,纳入nCRT后达cCR、初始拒绝手术并接受主动监测的食管癌患者41例。
- 临床反应评估包括18F-FDG PET/CT、内镜活检及内镜超声引导细针穿刺,按规律间隔进行。
- 测量原发肿瘤部位经瘦体重归一化的SUVmax(SULmax),计算末次随访扫描与nCRT后3个月扫描间的Δ%SULmax。
- 肿瘤复发定义为初始肿瘤部位活检证实有存活肿瘤。
主要发现
- 41例中24例在中位6.5个月(nCRT后)出现复发,17例在中位24个月随访期间保持无癌。
- 24例复发者中5例SULmax突然剧烈升高超过180%。
- 24例复发者中19例SULmax逐渐升高(中位Δ%SULmax +18%),持续cCR者SULmax下降(中位Δ%SULmax -12%),P<0.001(独立样本t检验)。
- 持续cCR患者SULmax在nCRT后11个月最低。
关键数值与推荐
- 肿瘤复发定义为初始肿瘤部位活检证实有存活肿瘤。
- 复发者中位Δ%SULmax为+18%,持续cCR者中位Δ%SULmax为-12%(P<0.001)。
- 5例复发者SULmax突然升高大于180%。
- 持续cCR者SULmax最低点出现在nCRT后11个月。
临床怎么用
- 对nCRT后cCR并选择主动监测的食管癌患者,可考虑系列18F-FDG PET/CT动态监测SULmax变化。
- 关注SULmax逐渐升高或突然剧烈升高,结合内镜活检等临床反应评估判断复发。
- nCRT后11个月左右SULmax最低,解读PET/CT时需考虑放射性食管炎的影响。
局限性
- 回顾性多中心设计,样本量较小(41例),结论需更大队列验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Active surveillance for patients with esophageal cancer and a clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) is being studied. Active surveillance requires accurate clinical response evaluations. 18F-FDG PET/CT might be able to detect local tumor recurrence after nCRT as soon as the esophagus recovers from radiation-induced esophagitis. The aims of this study were to assess the value of serial 18F-FDG PET/CT scans for detecting local recurrence in patients beyond 3 mo after nCRT and to determine when radiation-induced esophagitis has resolved. Methods: This retrospective multicenter study included patients who had cCR after nCRT, who initially declined surgery, and who subsequently underwent active surveillance. Clinical response evaluations included 18F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasound with fine-needle aspiration at regular intervals. SUVmax normalized for lean body mass (SULmax) was measured at the primary tumor site. The percentage change in SULmax (Δ%SULmax) between the last follow-up scan and the scan at 3 mo after nCRT was calculated. Tumor recurrence was defined as biopsy-proven vital tumor at the initial tumor site. Results: Of 41 eligible patients, 24 patients had recurrent disease at a median of 6.5 mo after nCRT and 17 patients remained cancer free during a median follow-up of 24 mo after nCRT. Five of 24 patients with tumor recurrence had sudden intense SULmax increases of greater than 180%. In 19 of 24 patients with tumor recurrence, SULmax gradually increased (median Δ%SULmax, +18%), whereas SULmax decreased (median Δ%SULmax, -12%) in patients with ongoing cCR (P < 0.001, independent-samples t test). In patients with ongoing cCR, SULmax was lowest at 11 mo after nCRT. Conclusion: Serial 18F-FDG PET/CT might be a useful tool for detecting tumor recurrence during active surveillance. In patients with ongoing cCR, the lowest SULmax was reached at 11 mo after nCRT, suggesting that radiation-induced esophagitis had mostly resolved by that time. These findings warrant further evaluation in a larger cohort.
引用
- Valkema MJ, van der Wilk BJ, Eyck BM, et al. Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy. J Nucl Med. 2020. PMID: 32887759. doi:10.2967/jnumed.120.247981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。